Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02691702 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 97
- Enrollment target
NCT02691702 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 97 participants.
The verdict
NCT02691702, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 97 participants
- Enrollment target
Study Summary
This is the first clinical trial to evaluate ascending multiple oral doses in healthy adult and healthy elderly subjects to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BIIB118
Interventions
- DRUG Melatonin
- DRUG BIIB118
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2016-03-28 |
| Est. Completion | 2017-01-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02691702
The ClinicalTrials.gov registry entry for NCT02691702 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Melatonin is the first listed.
NCT02691702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02691702 about?
NCT02691702 is a clinical study titled "Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers". This is the first clinical trial to evaluate ascending multiple oral doses in healthy adult and healthy elderly subjects to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BIIB118
What is the current status of trial NCT02691702?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2016-03-28. Estimated completion is 2017-01-12.
What interventions are being tested in trial NCT02691702?
The interventions under investigation include: Melatonin (DRUG), BIIB118 (DRUG).
Who is sponsoring clinical trial NCT02691702?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.